Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Aerosol Inhalation of MSCs-Exo in Severe COVID-19
NCT04276987Phase 1Completed
- Sponsor
- Ruijin Hospital
- Start
- Feb 2020
- Primary completion
- May 2020
- Countries
- 1
01
Overview
Phase 1, open-label trial in COVID-19 pneumonia, sponsored by Ruijin Hospital. Primary endpoints: Adverse reaction and severe adverse reaction up to 28 days and Time to clinical improvement up to 28 days. Started Feb 2020; status: completed.
02
Conditions
COVID-19 pneumonia
Beyond the preview
Go deeper on NCT04276987.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04276987.